Felipe Muñoz-Córdova,Carolina Hernández-Fuentes,Camila Lopez-Crisosto,Mayarling F. Troncoso,Ximena Calle,Alejandra Guerrero-Moncayo,Luigi Gabrielli,Mario Chiong,Pablo F. Castro,Sergio Lavandero

Abstract:Diabetic cardiomyopathy (DCM) is a severe complication of diabetes developed mainly in poorly controlled patients. In DCM, several clinical manifestations as well as cellular and molecular mechanisms contribute to its phenotype. The production of reactive oxygen species (ROS), chronic low-grade inflammation, mitochondrial dysfunction, autophagic flux inhibition, altered metabolism, dysfunctional insulin signaling, cardiomyocyte hypertrophy, cardiac fibrosis, and increased myocardial cell death are described as the cardinal features involved in the genesis and development of DCM. However, many of these features can be associated with broader cellular processes such as inflammatory signaling, mitochondrial alterations, and autophagic flux inhibition. In this review, these mechanisms are critically discussed, highlighting the latest evidence and their contribution to the pathogenesis of DCM and their potential as pharmacological targets.

Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies